CompletedPhase 1

A Study of [14C]-LY4064809 in Healthy Participants

United States7 participantsStarted 2026-03-27

Plain-language summary

The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 21 days, not including screening. Participants will remain in the clinical research center for 14 days.

Who can participate

Age range

18 Years – 55 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Must be healthy as shown by medical history, physical examination, laboratory tests and heart monitoring * Must have normal blood pressure and pulse rate * Must have a history of a minimum of 1 bowel movement per day * Must have body mass index (BMI) between 18 and 32 kilograms per square meter (kg/m2) * Must be healthy men or healthy women who are not of childbearing potential * Healthy men with partners who can become pregnant must remain abstinent or use contraceptives consistent with local regulations Exclusion Criteria: * Must not have a significant history or presence of metabolic disease, heart, liver, gallbladder, bile ducts, digestive, blood or nervous system disorders that could affect the way the body absorbs and processes the study drug * Must not have an abnormal electrocardiogram (ECG) * Must not have a history of major surgery within 30 days of entering study * Must not have a history of cancer within 5 years of screening * Must not have known allergies to LY4064809 or related compounds * Must not have history of multiple or severe drug reactions or allergies which required treatment with steroids or epinephrine * Must not have history or presence of psychiatric conditions that would prevent the participant from following study instructions. * Must not use medications, except acetaminophen within 14 days of the first dose of LY4064809 and during the clinic stay * Must not have participated in and been dosed in more than 2 radiolabeled d…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

To determine the absolute bioavailability (F) of LY4064809 following administration of a single oral dose compared to an intravenous reference dose in healthy participants.

Timeframe: Baseline up to Day 14

Trial details

NCT IDNCT07519525

SponsorEli Lilly and Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-05-26

View on ClinicalTrials.gov More Healthy trials